Dong Geng

机构：490 BioTech (United States)

发表论文 58 篇 · 总被引 2909 次 · h-index 17

代表论文

• CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma (2023 · Blood · 被引 99)
• CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma (2025 · New England Journal of Medicine · 被引 58)
• The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B) (2023 · Blood · 被引 29)
• Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up (2022 · Blood · 被引 26)
• Multi-Band Polarization Imaging in a Harsh Sea Fog Environment (2022 · Applied Sciences · 被引 11)
• Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors (2025 · Journal for ImmunoTherapy of Cancer · 被引 10)